Compare VTEX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTEX | ENGN |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | Cayman Islands | Canada |
| Employees | N/A | 82 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 647.1M |
| IPO Year | 2019 | N/A |
| Metric | VTEX | ENGN |
|---|---|---|
| Price | $3.87 | $7.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $5.97 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.2M | 501.8K |
| Earning Date | 05-05-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $10.57 | N/A |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.84 | $2.66 |
| 52 Week High | $6.82 | $12.25 |
| Indicator | VTEX | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 33.89 |
| Support Level | $3.68 | $6.03 |
| Resistance Level | $4.23 | $7.33 |
| Average True Range (ATR) | 0.20 | 0.66 |
| MACD | 0.03 | -0.18 |
| Stochastic Oscillator | 66.20 | 16.04 |
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.